Last reviewed · How we verify
NCT06083246
Clinical Efficacy of Hybenix vs Chlosite Gels in Peri-implantitis
NA trial testing Hybenix gel in Peri-Implantitis in 40 participants. Completed in 10 November 2025.
20 October 2025
Quick facts
| Lead sponsor | University of Pavia |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 10 October 2023 |
| Primary completion | 20 October 2025 |
| Estimated completion | 10 November 2025 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Hybenix gel
- Chlosite gel
Conditions studied
- Peri-Implantitis — all drugs for Peri-Implantitis →
Sponsor
University of Pavia
Who can join
Adults 18 to 70, any sex, with Peri-Implantitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The present study is a randomized clinical trial (RCT). Patients responding to the inclusion criteria will be included. The following peri-implant indexes will be collected: Bleeding On Probing, Gingival Bleeding Index, Marginal Mucosal Conditions (swelling and erythema), Suppuration, Mucosal margin migration, PPD Probing Pocket Depth, Plaque Index, Bleeding Score, radiographic bone loss. After the peri-implant evaluation, patients will undergo supragingival and subgingival professional oral hygiene of both arches performed with ultrasonic instrumentation with PEEK inserts, manual instrumentation with teflon curettes and air polishing with glycine powder. After that, the sample will be randomly divided into 2 groups based on thein-office assigned treatment: * Chlosite® gel application in the peri-implant sulcus * Hybenix® gel application for 30 s followed by rinsing of the peri-implant sulcus. The study will last 9 months. Patients will be visited at: T0, after 1 month from T0 (T1), after 3 months (T2), after 6 months (T3) and after 9 months (T4). In each time frame, indexes collection and nonsurgical debridement will be performed.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06083246
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Peri-Implantitis
Currently open trials in the same condition.
- NCT07012915 — Immunological-Clinical Evaluation of the Etiopathogenesis of Peri-Implantitis · NA · recruiting
- NCT06679283 — Surgical Treatment of Peri-implantitis With Adjunctive Application of Platelet Rich Fibrin (PRF) · NA · recruiting
- NCT06017817 — Antibacterial Photodynamic Therapy in the Management of Peri-implantitis · NA · recruiting
- NCT06364982 — Distance Between Dental Implants as a Risk Indicator for Peri-implant Disease. · recruiting
- NCT06288919 — Erythritol vs Ultrasonic Scaler Prophylaxis Systems on Dental Implants With Crowns Made by Different Materials · NA · active not recruiting
Other University of Pavia trials
Trials by the same sponsor.
- NCT07491536 — Ozone Therapy With Biomimetic Oral Care for Cancer-Related Oral Mucositis · NA · recruiting
- NCT07421128 — The Pause, Learn, and Activate Yourself (PLAY) · NA · not yet recruiting
- NCT07199712 — Ozone Therapy for Oral Mucositis in Patients Receiving Head and Neck Cancer Radio- and Chemotherapy · NA · completed
- NCT07088653 — Comparison of 0.12% Chlorhexidine and MicroRepair ABX Mouthwash in Gingivitis Management · NA · completed
- NCT07140146 — Trehalose vs Glycine Air-Polishing in Peri-Implant Mucositis Treatment · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06083246 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pavia
- Last refreshed: 18 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06083246.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing